QCR Holdings, Inc. Announces Annual Meeting Results and a Cash Dividend of $0.06 Per Share MOLINE, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- QCR Holdings, Inc. (NASDAQ: QCRH) today announced the election of four Class I directors at the Company’s annual meeting of its stockholders. The directors, Mary Kay Bates, John-Paul E. Besong, Todd A. Gipple, and Donna J. Sorenson, were re-elected to three-year terms. Additionally, on May 15, 2024, the Company’s Board of Directors declared a cash dividend of $0.06 per share payable on July 3, 2024, to holders of common stock of the Company of record o...
Varonis to Present at Upcoming Investor Conferences NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VRNS), a leader in data security, announced its participation at the following upcoming conferences: The J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference, May 20 – 22, in Boston. The presentation is scheduled for May 21 at 5:05 p.m. ET.The TD Cowen 52nd Annual Technology, Media & Telecom Conference, May 29 – 30, in New York. The presentation is scheduled for May 30 at 1:15 p.m. ET.The William Blair 44th Annual Growth Stock Conference, June 4 – 6, in Chica...
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a presentation at the European Hematology Association 2024 Congress, to be held June 13-16 in Madrid, Spain. “We’re excited to share the latest updated interim results from our Phase 1 trial evaluating our gamma-delta T cell therapy INB-100 after haploidentical stem cell transplantation for patients with leukemia at the upcoming EHA c...
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancerPhase 2 topline overall survival data for CAN-2409 in non-small cell lung cancer (NSCLC), to be presented at ASCO on June 3, 2024On track for topline disease-free survival data from CAN-2409 phase 3 clinical trial in localized intermediate/high risk prostate cancer, expected in Q4 2024 NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc....
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024 NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing platform across different donor populations, at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting. In an oral presentation titled: “Healthy Donor vs. Patient Manufac...
A director at Carriage Services Inc sold 21,186 shares at 25.840USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
A director at Herbalife Ltd bought 15,000 shares at 10.548USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue - Demonstrated potential of nsCAR platform to treat previously “undruggable” solid and liquid tumor targets - Announced peer-reviewed publication in ‘Frontiers in Immunology’ on IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI) approach to newly diagnosed glioblastoma multiforme (GBM) - Dosed first patient in auto...
BRT Apartments Corp. Files First Quarter 2024 Financial Statements GREAT NECK, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust that owns, operates, and, to a lesser extent, holds interests in joint ventures that own multi-family properties, announced that it has filed its quarterly report on Form 10-Q for the quarter ended March 31, 2024 with the Securities and Exchange Commission. The financial statements and can be accessed on the Company’s investor relations under the caption “Financials – Quarterly Results.” BRT is a real e...
Varonis Keynote at RSA Conference 2024: Preventing Your First AI Breach Varonis Vice President of Incident Response delves into the challenges of securing data in the age of AI NEW YORK and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- RSA CONFERENCE 2024 – (Nasdaq: VRNS), a leader in data security, is pleased to announce it will deliver a main stage keynote today at RSA Conference 2024 in San Francisco. Varonis Vice President of Incident Response and Cloud Operations Matt Radolec will present “Reducing AI's Blast Radius: How to Prevent Your First AI Breach” at 3:35 p.m. PT on the Mo...
Comscore Reports First Quarter 2024 Results RESTON, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Comscore, Inc. (Nasdaq: SCOR), a trusted partner for planning, transacting and evaluating media across platforms, today reported financial results for the quarter ended March 31, 2024. Q1 2024 Financial Highlights Revenue for the first quarter was $86.8 million compared to $91.6 million in Q1 2023Net loss of $1.1 million compared to $8.7 million in Q1 2023Adjusted EBITDA of $8.1 million compared to $5.2 million in Q1 2023Ma...
Varonis Wins Global InfoSec Award for Best DSPM at RSAC 2024 Cyber Defense Magazine honors the Varonis Data Security Platform for its exceptional DSPM capabilities NEW YORK and SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- RSA CONFERENCE 2024 – (Nasdaq: VRNS), a leader in data security, today announced it received the Best Data Security Posture Management Award for its exceptional DSPM capabilities from Cyber Defense Magazine (CDM), the industry's leading electronic information security magazine. Now in its 12th year, CDM's annual Global InfoSec Awards shine the spotlight on t...
Varonis Adds AI Prompt Monitoring to Prevent Malicious Copilot Activity Data security leader announces new capabilities to investigate risky Copilot interactions and stop AI-related data security breaches NEW YORK and SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- RSA Conference 2024 Booth #5658 — (Nasdaq: VRNS), a leader in data security, today announced the addition of prompt monitoring to its Microsoft 365 Copilot security offering. This new feature allows security teams to investigate risky prompts, responses, and sensitive file references directly within the Varonis Data Security...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.